AUTHORS
Hannah Goulart, MD, Elias Jabbour, MD2, Nitin Jain, MD3, Farhad Ravandi, MD4, Abhishek Maiti, MBBS5, Yesid Alvarado Valero, MD6, Alex Bataller, MD, PhD7, Jo Ishizawa, MD, PhD8, Wei Ying Jen, BM BCh, FRCPath9, Lucia Masarova, MD10, Jayastu Senapati, MBBS, MD, DM11, Mahesh Swaminathan, MD12, Christina Simon13, Christopher Loiselle, BS14, Rebecca Garris15, Guillermo Garcia-Manero, MD16, Nicholas Short, MD17, Hagop Kantarjian, MD18
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Older patients (pts) with B-cell acute lymphoblastic leukemia (B-ALL) have historically poor outcomes with conventional intensive therapy. The incorporation of immunotherapeutic agents, blinatumomab (Blina) and inotuzumab ozogamicin (InO) have led to improved outcomes. We hypothesized that earlier, dose-dense integration of blina and InO with lower-intensity chemotherapy would improve the outcomes by inducing early and deep molecular remissions that can translate to better survival. Here, we prospectively report the initial phase 2 trial results evaluating the dose-dense mini-CVD regimen in combination with InO and blina in older or unfit pts with newly diagnosed B-ALL.
Methods
Pts 60-70 years old or unfit (<60 years of age) for intensive chemotherapy with newly diagnosed Philadelphia (Ph) negative B-cell ALL were eligible. Pts received mini-hyper-CVD in combination with InO and blina in a dose-dense fashion: cycles 1, 3, 5 consisted of mini-hyper-CVD (cyclophosphamide 150 mg/m2 D1-3, vincristine 2mg D4, dexamethasone 20 mg D1-4, InO 0.6 mg/m2 D2 and 0.3 mg/m2 D8 [of C1], InO 0.3 mg/m2 D2 and 0.3 mg/m2 D8 [of C3], blina 9ug D4-5 and 28 ug D6-21 [of C1] and blina 28 ug D4-21 [of C3 and C5); cycles 2, 4, 6 consisted of mini-MTX and ara-C (MTX 250 mg/m2 D1, cytarabine 500 mg/m2 q12 hours D2-3, InO 0.3 mg/m2 D2 and 0.3 mg/m2 D8 [of C2 and C4], blina 28 mg D4-21), with Peg-G-CSF administered after each course. Pts received 12 IT chemotherapy administrations and rituximab if CD20 positive. All pts received ursodiol. Pts with high risk features (defined as the presence of TP53 mutation/low hypodiplody/tetraploidy, KMT2A-rearrangements, complex cytogenetics, Ph-like disease, or persistent measurable residual disease [MRD]) could proceed to CAR T-cell consolidation on protocol. Allogeneic stem cell transplant (SCT) was offered at the discretion of the treating MD.
Results
Between September 2022-March 2026, a total of 14 pts were enrolled; median age 65 years (range, 61-69); 8 pts (57%) were male. High-risk cytomolecular features were seen in 9 pts (64%), including 3 pts (21%) with Ph-like disease, 1 pt (7%) with KTMT2A-r, 1 pt (7%) with complex cytogenetics and 5 pts (36%) with mutations in TP53 (median VAF 17%, range [5-39%]).
Thirteen of 14 pts (93%) achieved a complete remission (CR), with all responding pts (100%) achieving MRD-negativity by multiparameter flow cytometry (MFC) overall, and 12/13 pts (92%) achieving MRD-negativity by MFC after cycle 1. A total of 11/12 pts (92%) became MRD-negative by next generation sequencing (NGS) overall, with 4 pts (33%) becoming NGS MRD-negative following cycle 1.
The median follow-up time is 19 months (0.95 CI 13 months – not reached). Six pts (43%) proceeded to CAR T consolidation (1 with obe-cel, 5 with brexu-cel), all pts who underwent CAR T remain alive in remission at last follow-up. At the time of CAR T infusion, all 6 pts (100%) were NGS MRD-negative. Of the remaining 8 pts (57%) who did not proceed to CAR T, 5 (63%) remain alive in remission, including 1 non-responding pt with a KMT2A-r who experienced a lineage switch, received myeloid salvage therapy and is currently alive in remission. Three pts (37%) died in CR (all from sepsis between cycles 4-6: 1 fungemia, 1 PJP pneumonia, and 1 ESBL Klebsiella bacteremia). No pts underwent SCT and no relapses were observed.
Neither the median event-free survival (EFS) nor overall survival (OS) have been reached. The estimated 2-year EFS and OS rates are 69% and 75%, respectively. These rates were superior to those observed in similar patients treated with sequential mini-CVD InO +/- blina; the 2-year EFS and OS rates were 61% and 66%, respectively. For pts proceeding to CAR T, the median OS and EFS are NR (2-year OS and EFS rates of both 100%), which compare favorably against historical expectations of patients with high-risk features who received sequential mini-CVD InO with blina (2-year OS and EFS rates of both 50%).
Conclusion
The dose-dense mini-CVD plus InO and blina regimen demonstrates robust activity in older and unfit pts with newly diagnosed Ph-negative B-ALL with MRD-negativity of 92% and 2-year EFS and OS rates of 69% and 75%, respectively. Sequential consolidation with CAR T-cell therapy in patients with high-risk features further improves the outcomes (2-year EFS and OS rates of both 100%). These findings support further evaluation of this regimen as a frontline approach in older adults with B-ALL.
DISCLOSURES
Hannah Goulart, MD: No relevant conflicts of interest to declare.